Diadexus, Inc. Stock

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
DDXSQ Stock

As early as today, start finding the best investment opportunities!

Market Cap	49.2K 44.24K 41.28K 37.41K 70.24K 4.68M 70.68K 495K 193K 2.43M 185K 181K 7.82M	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	5.29M 4.76M 4.44M 4.02M 7.55M 503M 7.6M 53.27M 20.8M 261M 19.86M 19.43M 840M	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI
09/05/18	Motion for Asset Sale Filed by Diadexus, Inc.	CI
01/08/16	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
29/07/16	Motion for Asset Sale Approved for Diadexus, Inc.	CI
29/07/16	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
20/07/16	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
07/07/16	Motion for Asset Sale Filed by Diadexus, Inc.	CI
07/07/16	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
13/06/16	Diadexus, Inc. Filed for Bankruptcy	CI
10/06/16	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
23/05/16	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
30/04/16	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIADEXUS, INC.	-.--%	-.--%	-	-	410
ELI LILLY AND COMPANY	+3.62%	+1.68%	+48.80%	+98.41%	1,077B
JOHNSON & JOHNSON	+2.13%	-1.76%	+33.04%	+61.88%	612B
ABBVIE INC.	+3.32%	+4.47%	+23.72%	+91.59%	501B
MERCK & CO., INC.	+3.80%	+3.21%	+73.99%	+41.69%	364B
ROCHE HOLDING AG	+1.39%	+6.49%	+32.21%	+48.96%	353B
NOVARTIS AG	+1.55%	+5.67%	+19.57%	+42.66%	278B
ASTRAZENECA PLC	+2.61%	+6.09%	-0.22%	+14.98%	251B
AMGEN INC.	+3.21%	+3.15%	+45.01%	+49.99%	230B
GILEAD SCIENCES, INC.	+3.80%	+4.56%	+29.59%	+97.73%	190B
Average	+1.60%	+1.77%	+33.97%	+60.88%	385.65B
Weighted average by Cap.	+1.75%	+1.58%	+37.43%	+69.48%

	2014	2015
Net sales	26.11M 23.48M 21.91M 19.86M 37.28M 2.48B 37.51M 263M 103M 1.29B 98.03M 95.91M 4.15B	17.88M 16.08M 15.01M 13.6M 25.53M 1.7B 25.69M 180M 70.32M 883M 67.14M 65.69M 2.84B
Net income	-8.47M -7.61M -7.1M -6.44M -12.09M -806M -12.16M -85.26M -33.29M -418M -31.79M -31.1M -1.35B	-7.17M -6.44M -6.01M -5.45M -10.23M -682M -10.29M -72.16M -28.18M -354M -26.9M -26.32M -1.14B
Net Debt	-198K -178K -166K -151K -283K -18.84M -284K -1.99M -778K -9.78M -743K -727K -31.45M	5.24M 4.71M 4.4M 3.99M 7.48M 499M 7.53M 52.77M 20.61M 259M 19.68M 19.25M 833M

Diadexus, Inc. Stock

Stocks

DDXSQ

US25245P2056

Pharmaceuticals

Valuation: Diadexus, Inc.

Latest news: Diadexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile